Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone720-643-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.39 million
Profitability
Miscellaneous
Employees77
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics Inc (NASDAQ:MGEN) issued its earnings results on Wednesday, August, 7th. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. The medical research company earned $2.51 million during the quarter, compared to analysts' expectations of $0.89 million. Miragen Therapeutics had a negative net margin of 925.52% and a negative return on equity of 85.50%. View Miragen Therapeutics' Earnings History.
When is Miragen Therapeutics' next earnings date?
What price target have analysts set for MGEN?
4 brokers have issued 1-year price objectives for Miragen Therapeutics' shares. Their forecasts range from $3.00 to $24.00. On average, they expect Miragen Therapeutics' share price to reach $15.17 in the next twelve months. This suggests a possible upside of 1,815.5% from the stock's current price. View Analyst Price Targets for Miragen Therapeutics.
What is the consensus analysts' recommendation for Miragen Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Miragen Therapeutics.
Has Miragen Therapeutics been receiving favorable news coverage?
Headlines about MGEN stock have trended negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Miragen Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Miragen Therapeutics.
Are investors shorting Miragen Therapeutics?
Miragen Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 688,700 shares, an increase of 55.4% from the August 30th total of 443,200 shares. Based on an average daily trading volume, of 223,600 shares, the short-interest ratio is presently 3.1 days. Currently, 2.8% of the shares of the stock are sold short. View Miragen Therapeutics' Current Options Chain.
Who are some of Miragen Therapeutics' key competitors?
What other stocks do shareholders of Miragen Therapeutics own?
Who are Miragen Therapeutics' key executives?
Miragen Therapeutics' management team includes the folowing people:
- Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)
- Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)
- Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)
- Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74)
How do I buy shares of Miragen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of MGEN stock can currently be purchased for approximately $0.79.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $24.59 million and generates $8.39 million in revenue each year. The medical research company earns $-32,700,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe.View Additional Information About Miragen Therapeutics.
What is Miragen Therapeutics' official website?
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
